Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 28 Jun 2023
In preclinical models, a recently identified radionuclide-based agent (CB-2PA-NT) has been demonstrated to have high tumor uptake, sustained tumor retention, and high contrast, making it an excellent candidate for a novel theranostics strategy.
Read Full NewsA secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
A Canadian cohort found modestly greater preeclampsia risk after donation, though most pregnancies were uncomplicated.
Future pregnancy plans don’t preclude living kidney donation, but candidates should be counseled on gestational hypertension risk.
Sparsentan Lowers Inflammatory, Complement Biomarkers in IgAN
Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant
1.
Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety
2.
healthy despite having advanced cancer.
3.
TKI Discontinuation Feasible After ALL Treatment
4.
De-escalation Misses the Mark in Inflammatory Breast Cancer
5.
Newly identified T-cell subtype may explain treatment-resistant childhood leukemia
1.
Treating Methemoglobinemia: What You Need to Know Now!
2.
Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions
3.
Virtual Survivorship Platforms in Cancer Care: Transforming Post-Treatment Support and Outcomes
4.
Exploring the Unseen: Carcinoid Syndrome and its Impact on Quality of Life
5.
Cancer Prehabilitation and Functional Recovery Pathways: An Evidence-Based Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
2.
Signs and Symptoms of Leukemia
3.
Efficient Management of First line ALK-rearranged NSCLC - Part III
4.
Navigating the Complexities of Ph Negative ALL - Part V
5.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge